Studies

Apellis Extension 314

Pediatrics Nephrology Kidney Disease Pediatric Subjects Adult Subjects

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

Apellis (PEGCETACOPLAN)--310

Pediatrics Nephrology Kidney Disease Pediatric Subjects Adult Subjects

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.

CLNP023B12301

Pediatrics Nephrology Kidney Disease Pediatric Subjects Adult Subjects

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol.

The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.